# NovaScan

> NovaScan is a Chicago-based clinical-stage oncology company building low-cost, point-of-care devices that detect cancer in real time. Its platform pairs spectral bioimpedance with machine learning around a single biophysical signal - the Cole relaxation frequency, which differs by orders of magnitude between cancerous and healthy tissue. Two lead products, nsCanary for assessing biopsy cores and MarginScan for checking surgical excision margins, aim to deliver answers in seconds instead of the days that conventional pathology can take.

- **Headquarters:** Chicago, Illinois, United States
- **Founders:** William Gregory (Founder / Inventor; emeritus professor and former Dean of Engineering, UW-Milwaukee), Craig Davis (President & CEO)
- **Team size:** approximately 14 employees
- **Products:** nsCanary, MarginScan, Cole Relaxation Frequency platform
- **Notable:** Identified and commercialized the Cole relaxation frequency as a single parameter distinguishing cancerous from non-cancerous tissue, Reported 91%-100% sensitivity and 85%-100% specificity across multiple cancer types in studies, Launched clinical trials in lung, pancreatic and GI cancers at major academic centers

## Products & services

- **nsCanary** — A digital 'smart ROSE' platform that assesses whether a biopsy core contains pathologically relevant cancer in seconds, giving near real-time feedback during endoscopic and needle biopsy procedures. Initial applications include pancreatic, biliary and lung biopsies.
- **MarginScan** — A compact device combining spectral bioimpedance with AI/ML to detect and localize cancer at the margins of surgical excisions in seconds. Non-destructive, requires no dedicated pathology resources, and is aimed first at Mohs skin-cancer surgery.
- **Cole Relaxation Frequency platform** — The underlying technology: NovaScan identified and uses the Cole relaxation frequency, an impedance parameter that increases roughly three orders of magnitude as cancer develops, giving near-zero overlap between cancerous and benign tissue.

## Achievements

- Identified and commercialized the Cole relaxation frequency as a single parameter distinguishing cancerous from non-cancerous tissue
- Reported 91%-100% sensitivity and 85%-100% specificity across multiple cancer types in studies
- Launched clinical trials in lung, pancreatic and GI cancers at major academic centers
- Raised an $8M Series B led by Builders VC (2021)
- Founders Craig Davis and William Gregory named WiSys 2022 Innovators of the Year
- Peer-reviewed publication in JMIR Biomedical Engineering on the Cole relaxation frequency in lung tissue

## Latest updates

- **2023-04** — Partnered with PHC Holdings to assess MarginScan for non-melanoma skin-cancer margins in Mohs surgery.
- **2021-11** — Closed an $8M Series B round led by Builders VC with Gore Range Capital.
- **2022** — Founders named WiSys Innovators of the Year; lung-tissue Cole relaxation frequency study published.

## Links

- Website: https://novascaninc.com
- LinkedIn: https://www.linkedin.com/company/novascaninc
- YouTube: https://www.youtube.com/@NovaScanAIOfficial

---

Profile page: https://yespress.io/novascan
Published by YesPress — https://yespress.io
Last updated: 2026-06-08